Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Industry News
Search Articles:
Astellas announces preliminary phase 1/2 safety, tolerability & efficacy data for ASP2215
Astellas Pharma announced preliminary data from a Phase 1/2 trial on safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia.
May 30, 2015
More...
Email This Page
to a Friend
Print This
Page